Systemic Diseases

LATEST NEWS

Plasma TNF-α, Adiponectin Levels Influence Risk for Psoriatic Arthritis, Psoriasis

By

Sheila Jacobs

The investigators sought to determine whether TNF-α and adiponectin levels might play a role in differentiating psoriatic arthritis from psoriasis.

B-Cell Depletion Therapy With Rituximab Effective for Cutaneous Lupus Erythematosus

By

Sheila Jacobs

Although patients with CCLE responded well, the numbers were small and additional research with respect to this finding is warranted.

Baricitinib Gets Fast Track Status for Systemic Lupus Erythematosus

By

Da Hee Han

Data from a Phase 2 trial of baricitinib for the treatment of SLE supporting the Fast Track designation were published in The Lancet and presented at the European Congress of Rheumatology earlier this year.

Assessment of Pediatric Cutaneous Lupus With CLASI Easier, More Reliable Than PGA

By

Sheila Jacobs

A majority of the physician participants reported that CLASI was an easier tool to use compared with PGA.

Depression Risk High in Cutaneous, Systemic Lupus Erythematosus

By

Sheila Jacobs

The risk for depression was increased significantly in patients with systemic lupus erythematosus and cutaneous lupus erythematosus.

Prevalence of Psoriatic Arthritis Quantified in Patients With Psoriasis

By

Sheila Jacobs

Researchers sought to estimate the occurrence of psoriatic arthritis in patients with psoriasis.

Glucocorticoid Cumulative Dose Has No Effect on BMD, Fracture Risk in Psoriasis, PsA

By

Haymarket Media

The objective of this cross-sectional analysis was to evaluate the prevalence of osteoporosis and frequency of fractures in patients with psoriasis or psoriatic arthritis.

Baseline Characteristics Associated With Response to Biologic Therapy in PsA

By

Sheila Jacobs

Researchers sought to compare baseline characteristics between patients with PsA who achieved and did not achieve minimal disease activity with biologic therapy.

CONTEST Not Superior to PEST Questionnaire for Diagnosing Psoriatic Arthritis

By

Sheila Jacobs

The CONTEST questionnaire includes the most discriminative questions from the three existing questionnaires.

Belimumab Aids Anti-dsDNA-Positive Hypocomplementemic Lupus

Weekly belimumab is associated with greater benefit than placebo for patients with hypocomplementemic/anti-double stranded (ds)DNA-positive systemic lupus erythematosus.